Sanofi has acquired Dynavax GmbH for $2,200,000,000. Dynavax GmbH, the European affiliate of Dynavax Technologies Corporation USA, based in Düsseldorf, Germany, is a commercial-stage biopharmaceutical company dedicated to developing and commercializing innovative vaccines for infectious diseases. This transaction represents a corporate acquisition, where Sanofi has bought Dynavax GmbH, rather than a funding round for the company.
Dynavax GmbH brings two significant commercial products to Sanofi's portfolio. Its HEPLISAV-B® vaccine, approved in the U.S. and European Union, provides protection against all known subtypes of hepatitis B virus in adults. Additionally, Dynavax's CpG 1018® adjuvant is a key component in multiple adjuvanted COVID-19 vaccines and is being advanced through global research collaborations for other adjuvanted vaccines, including those for seasonal influenza, universal influenza, plague, and shingles. Dynavax's more than 25 years of expertise in vaccine development and manufacturing, along with its recombinant protein production capabilities, further strengthens its value proposition.
This acquisition is strategic for Sanofi, allowing it to significantly enhance its vaccine pipeline and commercial offerings, particularly in adult infectious disease prevention. The addition of a marketed adult hepatitis B vaccine immediately expands Sanofi's product presence. The CpG 1018® adjuvant technology and its broader application in various vaccine collaborations also offer significant potential for future development and market expansion across Sanofi’s global infrastructure.
Expected synergies include leveraging Dynavax’s proven adjuvant technology and specialized manufacturing expertise within Sanofi’s extensive research, development, and commercialization capabilities. The integration aims to accelerate the development and market access of innovative vaccines. The combined entity is positioned to reinforce Sanofi's leadership in preventing infectious diseases, benefiting from Dynavax's established commercial products and advanced adjuvant platform to address critical public health needs globally.